N^α-Fmoc-Lys-OBzl | 236404-46-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: N^α-Fmoc-Lys-OBzl
• 英文别名: benzyl (((9H-fluoren-9-yl)methoxy)carbonyl)-L-lysine；(S)-benzyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-6-aminohexanoate；Fmoc-Lys-OBn；benzyl (2S)-6-amino-2-(9H-fluoren-9-ylmethoxycarbonylamino)hexanoate
• CAS: 236404-46-9
• 化学式: C₂₈H₃₀N₂O₄
• 分子量: 458.557
• InChiKey: IQQOKQGJGVWWAQ-SANMLTNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  90.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N^α-Fmoc-Lys-OBzl 在 palladium 10% on activated carbon 、 氢气 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 N-­Fmoc-­(2S)-­2-­amino-6-­(6-­phenylhexanamido)hexanoic acid
  参考文献：
  名称：

  Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1)

  摘要：

  We report herein that incorporating long-chain alkylphenyl-containing non-proteinogenic amino acids in place of His at the pT-2 position of the parent polo-like kinase 1 (Plk1) polo box domain (PBD)-binding pentapeptide, PLHSpT (1a) increases affinity. For certain analogs, approximately two orders-of-magnitude improvement in affinity was observed. Although, none of the new analogs was as potent as our previously described peptide 1b, in which the pT-2 histidine imidazole ring is alkylated at its pi nitrogen (N3), our current finding that the isomeric His(N1)-analog (1c) binds with approximately 50-fold less affinity than 1b, indicates the positional importance of attachment to the His imidazole ring. Our demonstration that a range of modified residues at the pT-2 position can enhance binding affinity, should facilitate the development of minimally-sized Plk1 PBD-binding antagonists. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.10.093
• 作为产物：
  描述：

  Fmoc-Lys(Boc)-OBn 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 N^α-Fmoc-Lys-OBzl
  参考文献：
  名称：

  用于癌症免疫治疗的蛋白酪氨酸磷酸酶 1B 和 T 细胞蛋白酪氨酸磷酸酶的小分子降解剂

  摘要：

  发现了蛋白酪氨酸磷酸酶 1B (PTP1B) 和 T 细胞蛋白酪氨酸磷酸酶 (TC-PTP) 抑制剂，并将其转化为针对这两个靶标的一流、有效、选择性的双 PROTAC 降解剂。该降解剂促进肿瘤细胞的抗原呈递并激活 CD8+ T 细胞。重要的是，该降解剂在体内有效并抑制同基因肿瘤生长。

  DOI：

  10.1002/anie.202303818

文献信息

• NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS
  申请人：Guichard Gilles

  公开号：US20100136034A1

  公开（公告）日：2010-06-03

  The invention relates to a compound of the formula (I): in which k and j are independently 0 or 1, Y is a macrocycle in which the cycle includes 9 to 36 carbon atoms and is functionalised by three amino functions and by a chain for attaching the spacer arm Z via an X bond, R c is a binding pattern with a receptor of the TNF superfamily, X is a chemical function for binding the Y group to the space arm, and Z is a bi-, tri- or tetra-functional spacer arm.

  该发明涉及以下式（I）的化合物： 其中k和j独立地为0或1，Y是一个大环，其中该环包括9至36个碳原子，并且通过三个氨基功能和通过链将间隔臂Z通过X键连接的功能化，Rc是与TNF超家族受体的结合模式，X是用于将Y基固定到空间臂的化学功能，Z是双功能、三功能或四功能间隔臂。
• Peptides for Treatment of Obesity
  申请人：Conde-Frieboes Kilian Waldemar

  公开号：US20130012432A1

  公开（公告）日：2013-01-10

  The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

  本发明涉及一种新型肽化合物，其有效调节一个或多个黑色素皮质素受体类型，以及该类化合物在治疗中的应用，包括通过将该类化合物用于需要的患者进行治疗的方法，以及该类化合物在制造药物中的应用。本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或症状方面具有特别的兴趣。
• [EN] STEROID CONJUGATE<br/>[FR] CONJUGUÉ DE STÉROÏDES<br/>[ZH] 一种甾体偶联物
  申请人：[en]DUALITY BIOLOGICS (SUZHOU) CO., LTD.;[zh]映恩生物制药（苏州）有限公司

  公开号：WO2022171101A1

  公开（公告）日：2022-08-18

  涉及一种甾体偶联物，具体涉及化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式，或其可药用的盐。还涉及本申请化合物的制备方法及其应用。
• Synthesis and antibacterial activity of amphiphilic lysine-ligated neomycin B conjugates
  作者：Smritilekha Bera、George G. Zhanel、Frank Schweizer

  DOI：10.1016/j.carres.2011.01.015

  日期：2011.4

  Amphiphilic lysine-ligated neomycin B building blocks were prepared by reductive amination of a protected C5 ''-modified neomycin B-based aldehyde and side chain-unprotected lysine or lysine-containing peptides. It was demonstrated that a suitably protected lysine-ligated neomycin B conjugate (NeoK) serves as a building block for peptide synthesis, enabling incorporation of aminoglycoside binding sites into peptides. Antibacterial testing of three amphiphilic lysine-ligated neomycin B conjugates against a representative panel of Gram-positive and Gram-negative strains demonstrates that C5 ''-modified neomycin-lysine conjugate retains antibacterial activity. However, in most cases the lysine-ligated neomycin B analogs display reduced potency against Gram-positive strains when compared to unmodified neomycin B or unligated peptide. An exception is MRSA where an eightfold enhancement was observed. When compared to unmodified neomycin B, the prepared lysine-neomycin conjugates exhibited a 4-8-fold enhanced Gram-negative activity against Pseudomonas aeruginosa and up to 12-fold enhanced activity was observed when compared to unligated reference peptides. (C) 2011 Elsevier Ltd. All rights reserved.
• Matsoukas; Hondrelis; Agelis, Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2958 - 2969
  作者：Matsoukas、Hondrelis、Agelis、Barlos、Gatos、Ganter、Moore、Moore

  DOI：——

  日期：——